



<b>Situation Report: Confirmed COVID-19</b>	<b>Location: The Gambia</b>
<b>Date of Report: 8<sup>th</sup>- 12<sup>th</sup> December 2021</b>	<b>Investigation Start Date: 17<sup>th</sup> March 2020 as of 18hrs.</b>
<b>Prepared by: Epidemiology and Disease Control Unit, MoH, The Gambia</b>	

## I. HIGHLIGHTS

This is the 407<sup>th</sup> national situation report since the confirmation of the first case of the coronavirus disease (COVID-19) in The Gambia, on the 16<sup>th</sup> March 2020

- No new COVID-19-related death registered, bringing the total to 342 (**Crude Case-Fatality Ratio, 3.4%**)
- 11 new cases were registered (**Cumulative cases 10,045**)
- Two (2), 3, 5 and 1 cases were registered on the 8<sup>th</sup> 9<sup>th</sup> 10<sup>th</sup> and 11<sup>th</sup>
- The test positivity rate is 0.66% (11/1657), NPHL –1594 (11 positives) and MRCG – 63 (0 Positives)
  - One (1) case is currently on oxygen therapy
- Three (3) case were discharged after at least 10 days from the day they tested positive but evaded institutional isolation and (1) from COVID-19 treatment centres
- As of 9<sup>th</sup> December 2021, the following number of people have been vaccinated with:
  - **Johnson & Johnson:**
    - Only 1 dose: 197,073
  - **Sinopharm:**
    - Dose 1: 4,468
    - Dose 2: 3,313
  - **AstraZeneca:**
    - Dose 1: 40,661
    - Dose 2: 27,880,
- **TARGET POPULATION**(based on microplanning estimates - 1,564,214)
  - Proportion of target population fully vaccinated (2 doses of AZ/Sinopharm OR 1 dose of J&J): 14.6%
  - Proportion of target population that received at least one Covid-19 vaccine dose (AZ OR J&J OR Sinopharm): 15.5%
- **TOTAL POPULATION** (Based on final MoH population projections for 2021 - 2,438,899)
  - Proportion of total population fully vaccinated (2 doses of AZ/Sinopharm OR 1 dose of J&J): 9.4%
  - Proportion of total population that received at least one Covid-19 vaccine dose (AZ OR J&J OR Sinopharm): 9.9%

### COVID-19 SITUATION IN NUMBERS

**Globally**

- 👤 Confirmed Cases: 270,683,889
- 👤 Recoveries: 243,414,505
- ➡ Deaths: 5,325,464


**Senegal**

- 👤 Confirmed Cases: 74,092
- 👤 Recoveries: 72,160
- ➡ Deaths: 1,886

**The Gambia**

- 👤 Confirmed Cases: 10,045
- 👤 Active Cases: 58
- 👤 Recoveries: 9,645
- ➡ Deaths: 342

## II. EPIDEMIOLOGICAL DESCRIPTION



**Fig 1: Geographic Distribution of Covid-19 Cases per 100,000 Pop. by Region Since the start of the Pandemic to 30<sup>th</sup> November (Number Above) and October only (Number below) in The Gambia**

- Western 1 Health Region has a disproportionately higher number of cases than all the health regions (**See Fig. 1**)
- Below are the age-sex distribution and the Epi-curve of confirmed cases by date of sample collection, respectively (**See Fig. 2 and 3**)




**Fig 2: Age-Sex Distribution of Confirmed COVID-19 Cases, The Gambia, 2021**

✱ This excludes the 27 confirmed cases whose demographic information are not yet available

About 59% of the confirmed cases are males (**See Fig. 2**)

About 59% of the confirmed cases are 40 years below (**See Fig. 2**)



**Fig. 3: Epidemic Curve of Laboratory-Confirmed Cases Reported daily, COVID-19 Pandemic, The Gambia, 16<sup>th</sup> March 2020-12<sup>th</sup> December 2021\*.**

A considerable amount of time elapsed between date of reporting and the date of laboratory confirmation of some cases

- Three main waves of infection occurred – the pre airport closure wave, the importation from Senegal wave and the intermittent airport re-opening and loosening of restrictions wave

**Table 1: Summary of New and Cumulative Public Health Response Outputs, COVID-19 Pandemic, The Gambia, 2021**

Status	New	Cumulative
No. of active cases in institutional isolation		2
No. of COVID-19 patients on oxygen support		4
No. of patients recovered and discharged	0	
In Hotel Quarantine	0	19
Completed Hotel Quarantine	0	5,240
Completed follow-up (asymptomatic people with travel history to affected countries) *	0	310
No. of Contact(s) Identified**	0	
No. of Contacts being monitored	0	
No. of Contacts who completed 14-day follow-up	0	17,119
No. of Contacts lost to follow-up	0	58
Total Tests conducted (Repeat Tests)***	1657(0)	128,891
Positive test result (Repeat Tests)***	11(0)	10,045
Negative test result (Repeat Tests)***	1646(0)	117,589
Inconclusive test result (Repeat Tests)***	0(0)	

\* Follow-up completed prior to the 17<sup>th</sup> March (when the first confirmed case was reported)

\*\* Includes both low-risk and high-risk contacts and not mutually exclusive with number quarantined (as some have been quarantined)

\*\*\* Includes repeat tests in bracket

Table 2: Summary by region (Total doses administered from the beginning of Covid-19 vaccination in The Gambia)

Region	29-Nov	30-Nov	01-Dec	02-Dec	03-Dec	04-Dec	05-Dec	06-Dec	07-Dec	08-Dec	09-Dec	Total
CRR	0	107	0	0	381	0	0	0	164	0	403	1,055
LRR	0	0	0	0	0	0	0	23	0	0	31	54
NBER	20	0	0	104	0	0	0	0	0	134	68	326
NBWR	0	62	0	0	0	0	0	0	0	0	0	62
URR	153	274	0	336	98	0	0	0	536	0	0	1,397
WR1	74	108	305	128	61	0	0	45	55	0	0	776
WR2	0	0	400	164	0	0	0	0	0	0	200	764
<b>Total</b>	<b>247</b>	<b>551</b>	<b>705</b>	<b>732</b>	<b>540</b>	<b>0</b>	<b>0</b>	<b>68</b>	<b>755</b>	<b>134</b>	<b>702</b>	<b>4,434</b>

Table 3: Major response activities undertaken newly, COVID-19 Outbreak, The Gambia, 2021

### III. MAJOR RESPONSE ACTIVITIES

Component	Interventions
Coordination	<ul style="list-style-type: none"> <li>Coordination meetings held at both central and regional levels</li> </ul>
Surveillance/ Laboratory	<ul style="list-style-type: none"> <li>A total of <b>1657</b> new laboratory test results received <b>1594</b> from <b>NPHL</b> and <b>63</b> from <b>MRCG</b> <ul style="list-style-type: none"> <li>Of these, <b>no</b> test result returned inconclusive or indeterminate, <b>11</b> new samples tested positive</li> </ul> </li> </ul>
Case Management / Psychosocial Support & Research / IPC	<ul style="list-style-type: none"> <li><b>No</b> new COVID-19 related death recorded</li> <li><b>One (1)</b> patient was newly discharged from treatment centres</li> <li><b>No</b> new contacts traced and monitored</li> <li><b>One (1)</b> COVID-19 patients are currently on oxygen therapy</li> </ul>

### IV. GAPS/CHALLENGES:

- CBS activities not replicated in all regions to increase in the number of daily tests being conducted
- Support for innovative countrywide risk communication strategies and activities on COVID-19 is suboptimal
- Dwindling compliance with mask-wearing requirements
- Low turn-out at COVID-19 sample collection sites resulting in fewer number of daily tests
- Denial, misinformation, stigma and discrimination against COVID-19 affected families.
- Low COVID-19 vaccination coverage rate

### V. NEXT STEPS/RECOMMENDATIONS:

- CBS activities need to be synchronized with MRC's ILI surveillance to spur up testing rates in the hinterland.
- Strengthen community-based surveillance in all regions to increase awareness and testing rates
- Intensify risk communication and community engagement activities, on COVID-19 at community level, including at LUMOS, in a bid to curtail community transmission and dispel misinformation and denial and vaccine hesitancy
- Thorough enforcement of the mandatory mask-wearing regulation
- IPC measures should be strictly adhered to in all public and private health healthcare facilities
- Provision of adequate stocks of PPEs to all health facilities

- Health workers to observe all COVID-19 preventive measures always including the donning of appropriate PPEs
- Intensify activities geared to increase COVID-19 vaccination coverage at all levels
- Strengthen the capacity of the National Public Health Laboratories to conduct sequencing to identify new variants from positive samples as the COVID-19 virus evolves.

**For comments or questions, please contact:**  
**Sana M. Sambou**  
 Public Health Emergency Operations Center  
 Epidemiology and Disease Control Unit, The Gambia  
**Email:** [sanamsambou@hotmail.com](mailto:sanamsambou@hotmail.com)     **Phone:** +220 3516320/2422949/3921415

**PARTNERS**

